- Conditions
- T2DM (Type 2 Diabetes Mellitus), Continuous Glucose Monitoring
- Interventions
- iPro2 Professional CGM
- Device
- Lead sponsor
- East Tennessee State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Johnson City, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 5,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Amyloidosis
- Interventions
- Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Comfort
- Interventions
- The Richards-Campbell Sleep Questionnaire (R-CSQ), Revised American Pain Society Outcome Questionnaire (APS-POQ-R)
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
- Device
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
- Interventions
- Direct Selective Laser Trabeculoplasty (DSLT)
- Device
- Lead sponsor
- Ngoc Nguyen Inc.
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Leukemia
- Interventions
- flow cytometry, immunologic technique, laboratory biomarker analysis
- Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 2
- States / cities
- Kinston, North Carolina • Columbus, Ohio
- Conditions
- Exposure to Man-made Visible Light
- Interventions
- 670 nm light, octafluropropane
- Device · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Drusen Stage Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Carl Zeiss Meditec, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Oakland, California • San Francisco, California • Miami, Florida + 1 more
- Conditions
- Nicotine Dependence, Smoking Cue Reactivity, Relapse to Smoking
- Interventions
- [11C]-PHNO
- Radiation
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 3
- States / cities
- Belmont, Massachusetts • Boston, Massachusetts • Charlestown, Massachusetts
- Conditions
- Toxoplasma Infections
- Interventions
- toxoplasma ICT IgG-IgM BK
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypertension, Diabetes Mellitus, Type 2
- Interventions
- Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
- Drug · Device · Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 35 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Stroke, Delirium, Spatial Neglect
- Interventions
- Confusion Assessment Method, Behavioral Inattention Test, Magnetic Resonance Imaging, Florida Mental Status Examination, Montreal Cognitive Assessment, Geriatric Depression Scale, Kessler Foundation Neglect Assessment Process
- Diagnostic Test
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- West Orange, New Jersey • New York, New York
- Conditions
- Overweight and Obesity, Adolescent Obesity, Exercise
- Interventions
- Aerobic exercise, Isometric exercise
- Other
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Graft Versus Host Disease, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
- Interventions
- palifermin, flow cytometry, laboratory biomarker analysis, pharmacological study
- Biological · Other
- Lead sponsor
- Martin, Paul
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
- Interventions
- measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
- Device
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Sleep Disorder
- Interventions
- Monitoring Sleep, stress biomarkers
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 100 participants
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pulmonary Hypertension
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
- Interventions
- Pioglitazone
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
- Conditions
- Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
- Interventions
- Control:Diabetes mobile app
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiac Disease, Respiratory Disease, Congenital Cardiac Defect, Cardiovascular Diseases, Chronic Respiratory Disease, Chronic Cardiopulmonary Disease, Premature Infant Disease
- Interventions
- Gabi System
- Device
- Lead sponsor
- Gabi SmartCare
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • New York, New York
- Conditions
- Astigmatism
- Interventions
- Not listed
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Normal Tension Glaucoma
- Interventions
- Gingko Baloba, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Robert Ritch, MD, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Aging
- Interventions
- L[ring-13C6]phenylalanine
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota